- Nano cap biotech Rexahn Pharmaceuticals (RNN) enjoys a pop in today's trading. Shares have eased a bit from the intraday high of $1.47, but are still up ~9% at $1.36.
- The firm disclosed initial results from its Phase 1 clinical trial of Supinoxin (RX-5902). Three patients have received two - six cycles of treatment. All doses were well tolerated.
- Some observers perceive the action as proof of investors' overexuberance with all things biotech.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs